Cargando...
A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors
BACKGROUND: Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to...
Gardado en:
| Publicado en: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8058950/ https://ncbi.nlm.nih.gov/pubmed/33423090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04224-8 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|